Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Cancer Lett
    November 2017
  1. KIM YJ, Sung D, Oh E, Cho Y, et al
    Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
    Cancer Lett. 2017;412:118-130.
    >> Share

    October 2017
  2. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals" [Cancer Lett. 386 (2017) 12-23].
    Cancer Lett. 2017 Oct 30. pii: S0304-3835(17)30662.
    >> Share

  3. BAI XY, Li S, Wang M, Li X, et al
    Kruppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.
    Cancer Lett. 2017;412:224-235.
    >> Share

  4. SYNNOTT NC, Bauer MR, Madden S, Murray A, et al
    Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Cancer Lett. 2017 Oct 22. pii: S0304-3835(17)30622.
    >> Share

  5. WILMANSKI T, Zhou X, Zheng W, Shinde A, et al
    Inhibition of Pyruvate Carboxylase by 1alpha,25-Dihydroxyvitamin D Promotes Oxidative Stress in Early Breast Cancer Progression.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30606.
    >> Share

  6. SOHN EJ, Jung DB, Lee H, Han I, et al
    CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30621.
    >> Share

  7. FIGUEIRA MI, Cardoso HJ, Correia S, Maia CJ, et al
    The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?
    Cancer Lett. 2017;405:10-21.
    >> Share

    September 2017
  8. MARINO S, Bishop RT, Logan JG, Mollat P, et al
    Pharmacological evidence for the bone-autonomous contribution of the NFkappaB/beta-catenin axis to breast cancer related osteolysis.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30587.
    >> Share

  9. OLADAPO HO, Tarpley M, Sauer SJ, Addo KA, et al
    Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30586.
    >> Share

  10. XU H, Lin F, Wang Z, Yang L, et al
    CXCR2 Promotes Breast Cancer Metastasis and Chemoresistance via suppression of AKT1 and activation of COX2.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30583.
    >> Share

  11. WANG S, Zhou R, Sun F, Li R, et al
    The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30551.
    >> Share

    August 2017
  12. WANG B, Zhao H, Zhao L, Zhang Y, et al
    Up-regulation of OLR1 expression by TBC1D3 through activation of TNFalpha/NF-kappaB pathway promotes the migration of human breast cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30508.
    >> Share

  13. QIN H, Liu X, Li F, Miao L, et al
    PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30506.
    >> Share

  14. FALLATAH M, Liu S, Sevigny MB, Zou H, et al
    Novel flexible heteroarotinoid, SL-1-18, promotes ERalpha degradation to inhibit breast cancer cell growth.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30513.
    >> Share

  15. AMUNJELA JN, Tucker SJ
    POPDC1 is suppressed in human breast cancer tissues and is negatively regulated by EGFR in breast cancer cell lines.
    Cancer Lett. 2017;406:81-92.
    >> Share

    May 2017
  16. YU ZH, Lun SM, He R, Tian HP, et al
    The dual function of MAZ mediated by FOXF2 in basal-like breast cancer: Suppression of progression but promotion of proliferation.
    Cancer Lett. 2017 May 31. pii: S0304-3835(17)30356.
    >> Share

    April 2017
  17. WU YH, Hong CW, Wang YC, Huang WJ, et al
    A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
    Cancer Lett. 2017 Apr 24. pii: S0304-3835(17)30283.
    >> Share

  18. LUI AJ, Geanes ES, Ogony J, Behbod F, et al
    IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
    Cancer Lett. 2017 Apr 12. pii: S0304-3835(17)30235.
    >> Share

    March 2017
  19. DESHMUKH SK, Srivastava SK, Zubair H, Bhardwaj A, et al
    Resistin potentiates chemoresistance and stemness of breast cancer cells: implications for racially disparate therapeutic outcomes.
    Cancer Lett. 2017 Mar 13. pii: S0304-3835(17)30174.
    >> Share

  20. MONTEIRO FL, Vitorino R, Wang J, Cardoso H, et al
    The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells.
    Cancer Lett. 2017 Mar 10. pii: S0304-3835(17)30171.
    >> Share

  21. LI Y, Li J, Zhang Y, Wang Y, et al
    Roles of Cancer/Testis Antigens (CTAs) in Breast Cancer.
    Cancer Lett. 2017 Mar 5. pii: S0304-3835(17)30148.
    >> Share

    February 2017
  22. BURNETT JP, Lim G, Li Y, Shah RB, et al
    Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Cancer Lett. 2017 Feb 27. pii: S0304-3835(17)30132.
    >> Share

  23. ZHANG Z, Zhu Y, Wang Z, Zhang T, et al
    Yin-Yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy.
    Cancer Lett. 2017 Feb 16. pii: S0304-3835(17)30108.
    >> Share

    January 2017
  24. MONTAGNA E, Palazzo A, Maisonneuve P, Cancello G, et al
    Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
    Cancer Lett. 2017 Jan 26. pii: S0304-3835(17)30068.
    >> Share

  25. RESZKA E, Przybek M, Muurlink O, Peplonska B, et al
    Circadian gene variants and breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30035.
    >> Share

  26. BUI QT, Im JH, Jeong SB, Kim YM, et al
    Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30037.
    >> Share

  27. MENDOZA-RODRIGUEZ M, Romero HA, Fuentes-Panana EM, Ayala-Sumuano JT, et al
    IL-1beta induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30025.
    >> Share

  28. MUNZONE E, Colleoni M
    Metronomics in the neoadjuvant and adjuvant treatment of breast cancer.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30026.
    >> Share

  29. HUANG R, Yu Y, Zong X, Li X, et al
    Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1alpha.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30020.
    >> Share

    December 2016
  30. BHARTI R, Dey G, Banerjee I, Dey KK, et al
    Somatostatin Receptor Targeted Liposomes with Diacerein Inhibit IL-6 for Breast Cancer Therapy.
    Cancer Lett. 2016 Dec 23. pii: S0304-3835(16)30784.
    >> Share

  31. CAZZANIGA ME, Dionisio MR, Riva F
    Metronomic chemotherapy for advanced breast cancer patients.
    Cancer Lett. 2016 Dec 23. pii: S0304-3835(16)30782.
    >> Share

  32. MULUHNGWI P, Krishna A, Vittitow SL, Napier JT, et al
    Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
    Cancer Lett. 2016;388:230-238.
    >> Share

    November 2016
  33. KIM JY, Lee N, Kim YJ, Cho Y, et al
    Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
    Cancer Lett. 2016 Nov 25. pii: S0304-3835(16)30710.
    >> Share

  34. TU M, Li Z, Liu X, Lv N, et al
    Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor beta 1 and hypoxia dependent repression of GATA-binding factor 3.
    Cancer Lett. 2016 Nov 17. pii: S0304-3835(16)30704.
    >> Share

  35. ZYSK A, DeNichilo MO, Panagopoulos V, Zinonos I, et al
    Adoptive transfer of ex vivo expanded Vgamma9Vdelta2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Cancer Lett. 2016 Nov 16. pii: S0304-3835(16)30699.
    >> Share

  36. LIANG YK, Zeng, Xiao YS, Wu Y, et al
    MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERalpha expression and AKT activation.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30682.
    >> Share

  37. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30681.
    >> Share

  38. JI X, Peng Z, Li X, Yan Z, et al
    Neutralization of TNFalpha in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
    Cancer Lett. 2016 Nov 7. pii: S0304-3835(16)30662.
    >> Share

    October 2016
  39. WANG X, Wei S, Zhao Y, Shi C, et al
    Anti-proliferation of breast cancer cells with itraconazole: hedgehog pathway inhibition induces apoptosis and autophagic cell death.
    Cancer Lett. 2016 Oct 31. pii: S0304-3835(16)30665.
    >> Share

  40. VENNIN C, Spruyt N, Robin YM, Chassat T, et al
    The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.
    Cancer Lett. 2016 Oct 22. pii: S0304-3835(16)30644.
    >> Share

  41. KIKUCHI M, Katoh H, Waraya M, Tanaka Y, et al
    Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
    Cancer Lett. 2016 Oct 15. pii: S0304-3835(16)30629.
    >> Share

  42. MIMOTO R, Nihira NT, Hirooka S, Takeyama H, et al
    Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
    Cancer Lett. 2016 Oct 13. pii: S0304-3835(16)30627.
    >> Share

  43. TU M, Lu C, Lv N, Wei J, et al
    Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2.
    Cancer Lett. 2016 Oct 1. pii: S0304-3835(16)30573.
    >> Share

    September 2016
  44. DI MODICA M, Regondi V, Sandri M, Iorio MV, et al
    Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30555.
    >> Share

  45. XU J, Han M, Shen J, Guan Q, et al
    2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30553.
    >> Share

  46. ZHU J, Zhou Q, Tan S
    Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30563.
    >> Share

  47. ZHANG Y, Zhang J, Liu C, Du S, et al
    Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Cancer Lett. 2016 Sep 2. pii: S0304-3835(16)30511.
    >> Share

    July 2016
  48. MARZEC KA, Martino-Echarri E, Irminger-Finger I, Henderson BR, et al
    BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin.
    Cancer Lett. 2016 Jul 28. pii: S0304-3835(16)30453.
    >> Share

  49. PLUCHINO LA, Choudhary S, Wang HR
    Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
    Cancer Lett. 2016 Jul 28. pii: S0304-3835(16)30455.
    >> Share

  50. GARI HH, DeGala GD, Ray R, Lucia MS, et al
    PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
    Cancer Lett. 2016;380:505-512.
    >> Share

  51. PAVLOPOULOU A, Oktay Y, Vougas K, Louka M, et al
    Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
    Cancer Lett. 2016;380:485-493.
    >> Share

  52. UGOLKOV A, Gaisina I, Zhang JS, Billadeau DD, et al
    GSK-3 inhibition overcomes chemoresistance in human breast cancer.
    Cancer Lett. 2016 Jul 14. pii: S0304-3835(16)30400.
    >> Share

  53. ROSSETTI S, Bshara W, Reiners JA, Corlazzoli F, et al
    Harnessing 3D models of mammary epithelial morphogenesis: An off the beaten path approach to identify candidate biomarkers of early stage breast cancer.
    Cancer Lett. 2016 Jul 13. pii: S0304-3835(16)30397.
    >> Share

  54. WU J, Ding Y, Chen CH, Zhou Z, et al
    A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
    Cancer Lett. 2016 Jul 4. pii: S0304-3835(16)30393.
    >> Share

    June 2016
  55. LI XQ, Lu JT, Tan CC, Wang QS, et al
    RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha5-mediated colonization.
    Cancer Lett. 2016 Jun 15. pii: S0304-3835(16)30367.
    >> Share

  56. BAPU D, Runions J, Kadhim M, Brooks SA, et al
    N-acetylgalactosamine glycans function in cancer cell adhesion to endothelial cells: A role for truncated O-glycans in metastatic mechanisms.
    Cancer Lett. 2016;375:367-74.
    >> Share

  57. CHEN KH, Walker AM
    Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
    Cancer Lett. 2016;375:293-302.
    >> Share

    May 2016
  58. KIM JY, Cho Y, Oh E, Lee N, et al
    Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
    Cancer Lett. 2016 May 26. pii: S0304-3835(16)30339.
    >> Share

  59. SASAKI S, Baba T, Nishimura T, Hayakawa Y, et al
    Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis.
    Cancer Lett. 2016;378:23-32.
    >> Share

  60. NUTA O, Somaiah N, Boyle S, Chua ML, et al
    Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
    Cancer Lett. 2016;374:324-30.
    >> Share

    April 2016
  61. REN Y, Zhou X, Liu X, Jia HH, et al
    Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy.
    Cancer Lett. 2016;374:96-106.
    >> Share

    March 2016
  62. JACOB J, Favicchio R, Karimian N, Mehrabi M, et al
    LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.
    Cancer Lett. 2016;372:137-46.
    >> Share

  63. JAKHAR R, Paul S, Bhardwaj M, Kang SC, et al
    Astemizole-Histamine induces Beclin-1-independent autophagy by targeting p53-dependent crosstalk between autophagy and apoptosis.
    Cancer Lett. 2016;372:89-100.
    >> Share

  64. XU Z, Wang Z, Jia X, Wang L, et al
    MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Cancer Lett. 2016;372:118-27.
    >> Share

    February 2016
  65. KAWPRASERTSRI S, Pietras RJ, Marguez-Garban DC, Boonyaratanakornkit V, et al
    Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells.
    Cancer Lett. 2016 Feb 15. pii: S0304-3835(16)30068.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016